頁籤選單縮合
| 題 名 | 戒酒藥物治療Naltrexone=Pharmacotherapy for Alcohol Use Disorder--Naltrexone |
|---|---|
| 作 者 | 黃思瑩; 楊淑瑜; 官玫秀; | 書刊名 | 藥學雜誌 |
| 卷 期 | 34:3=136 2018.09[民107.09] |
| 頁 次 | 頁79-84 |
| 分類號 | 415.8752 |
| 關鍵詞 | 酒精使用障礙症; 酒精依賴; 酒精濫用; Naltrexone; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 酒癮,在 DSM-V 裡的正式診斷名稱為-酒精使用障礙症 (Alcohol use disorder, AUD),是合併 DSM-IV 診斷裡酒精濫用 (Alcohol Abuse) 及酒精依賴 (Alcohol Dependence)。酒精使用障礙症的治療以減低飲酒攝取量為目標,對於一些重度飲酒 者,還無意願完全戒酒的個案,藉由藥物治療合併心理治療,能降低飲酒頻率或飲酒 攝取量,以改善個人健康。Naltrexone 作用機轉為競爭性阻斷鴉片類受體,降低對酒 精的渴求,預防病人重度飲酒,降低健康風險。但 naltrexone 在國內還沒有取得藥品 許可證,台灣的使用經驗有限,臨床醫療人員處方該藥時須小心謹慎,不可與鴉片類 藥品併用,以免產生戒斷症狀,同時須監測肝功能,充分衛教病人。 |
| 英文摘要 | Alcohol abuse and alcohol dependence in DSM-IV were integrated into alcohol use disorder defined in DSM-V. The primary purpose of alcohol use disorder treatment is to decrease intake of alcohol. Drug therapy is combined with psychological therapy to lower drinking frequency and alcohol intake and improve life quality for those heavy drinking alcoholic patients. Naltrexone is a competitive antagonist of opioid receptor to reduce the craving of alcohol, prevent heavy drinking and lower health risk. However naltrexone is not approved in TFDA yet, which limits its using experiences in Taiwan. Clinicians should prescribe cautiously. Patients who are prescribed naltrexone should not concomitantly use with opioid drugs to prevent withdrawal syndromes and monitor their liver functions. |
本系統中英文摘要資訊取自各篇刊載內容。